Pulmonary Artery Denervation for Pulmonary Hypertention in Patients with Connective Tissue Diseases (The PADN-3 trial): a randomised controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004417

Enrollment

Unknown

Registered

2014-04-23

Start date

2014-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Connective tissue diseases combined pulmonary hypertension

Interventions

Treat group:Pulmonary Artery Denervation

Control group:Medication

Eligibility

Sex/Gender

All

Age

5 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. pulmonary artery hypertension secondary from connective-tissue diseases; 2. Mean pulmonary artery pressure>=25 mmHg(Resting), or >=30 mmHg(Exercise); 3. Voluntary acceptance of all follow-up assessment of program requirements.

Exclusion criteria

Exclusion criteria: 1. Pulmonary artery hypertension secondary from atrial septal defect, or from ventricular septal defect, or from patent duct artery; 2. Renal dysfunction; 3. Liver dysfunction; 4. Blood platelet count=70%; 6. History of percutaneous coronary intervention or coronary artery bypass graft; 7. Family history of syncope of unknown reasons; 8. Expected life span<12-month; 9. In pregnance; 10. Systematical inflammation; 11. Malignant cancer(s); 12. Tricuspid valve stenosis; 13. Supra-pulmonary valve stenosis; 14. Dianosed deep venous thrombus<3-month; 15. Allergic to studied drugs; 16. Allergic to metal materials; 17. Normal thyroid function; 18. Inferior vena cava normal.

Design outcomes

Primary

Measure	Time frame
Systolic pulmonary artery pressure;	—

Countries

China

Contacts

Public ContactShao-Liang Chen

Nanjing First Hospital, Nanjing Medical Hospital

chmengx@126.com+86 13605157029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026